Innovation

All categories



News Center

Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US! 2024-08-14 11:55:51

Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.

Viwit Pharmaceutical's Varenicline Tartrate Tablet receives official approval from South Africa 2024-07-15 10:01:41

Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).

Viwit Pharmaceutical's Fosaprepitant Dimeglumine API Receives Official Approval from NMPA 2024-07-12 09:12:19

On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.

In-/Out-Licensing

Categories:Innovation Collaboration Platform
Time of issue:2020-01-23 00:00:00
Views:0

Description:

Information

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

Viwit is highly interested in collaborative opportunities including product license-in and license-out, co-research/co-development, co-promotion/co-marketing, and with partners including research institutes, pharmaceutical companies, and biotech companies domestically and internationally.

Scan the QR code to read on your phone



search

Confirm

Close

About Us

R&D and Innovation

Products

Innovation

Sustainable

News Center

Join Us

Contact Us

VIWIT 沪ICP备12014533号-2 Terms of Use

EN

中文